Search Names & Symbols

With personal love and passion we work alone and analyze our favorite shares. May not be many, but they are worth it.

The best online stock broker. Open an account today and start earning up to $1000 of IBKR Stock !

Sunday, February 27, 2022

The shares of our page with the best and worst performance of the week

 The financial and technical analycies presented on this website have not been performed by an Investment Services Company, nor have they been compiled by a certified analyst . It is simply a display and presentation of public data of Greek and foreign shares with informative and entertaining character.



Chevron Corp (CVX:NYSE)


Motor Oil (MOH.AT)


Sage Therapeutic (SAGE)





Volta Industries Inc (VLTA:NASDAQ)


Alibaba (BABA.NYSE)


Zepp Health (ZEPP:NASDAQ)




IMPORTANT POSTS

BAYERN - GOLDEN CROSS

Hellenic Telecommunications: 52 week high



MYTILINEOS financial results 2004-2021

 

MYTILINEOS financial results 2004-2021


Saturday, February 26, 2022

YANDEX - CONTRA

  click on the arrows

YANDEX -CONTRA by StockBlog on TradingView.com

Hellenic Telecommunications: 52 week high

 




Friday, February 25, 2022

UNIPRO-CONTRA

UNIPRO-CONTRA by StockBlog on TradingView.com


 click on the arrows

BEAR IS NEAR...

Thursday, February 24, 2022

SAGE: F INANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021

 INANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021

  • Cash Position: Cash, cash equivalents and marketable securities as of December 31, 2021 were $1.7 billion compared to $1.8 billion at September 30, 2021.
  • Revenue: Net revenue from sales of ZULRESSO was $1.6 million in the fourth quarter of 2021 compared to $1.7 million in the same period of 2020. For the year ended December 31, 2021, net revenue from sales of ZULRESSO was $6.3 million compared to $6.7 million in the same period of 2020. Additionally, in the fourth quarter of 2020, Sage recorded $1.1 billion of collaboration revenue from Biogen that consisted of an upfront payment of $875 million plus $232.5 million in excess proceeds from the equity investment under the stock purchase agreement.
  • R&D Expenses: Research and development expenses were $75.4 million, including $9.1 million of non-cash stock-based compensation expense, in the fourth quarter of 2021 compared to $81.7 million, including $10.1 million of non-cash stock-based compensation expense, for the same period in 2020. For the year ended December 31, 2021, R&D expenses were $283.2 million, including $49.7 million of non-cash stock-based compensation expense, compared to $292.7 million, including $42.4 million of non-cash stock-based compensation expense, for the same period in 2020. For the year, the decrease in R&D expenses was primarily due to the reimbursement from Biogen of $79.8 million pursuant to the Sage/Biogen Collaboration and License Agreement, partially offset by an increase in spending of $70.3 million. The increase in spending was mainly attributable to increased spending on zuranolone and Sage’s wholly owned pipeline including SAGE-718 and other programs. For the year, non-cash stock-based compensation expense increased because the Company incurred $9.8 million of expense in 2021 due to the achievement of milestones for certain outstanding performance restricted stock units and incurred no expense for such grants in 2020.
  • SG&A Expenses: Selling, general and administrative expenses were $51.6 million, including $11.5 million of non-cash stock-based compensation expense, in the fourth quarter of 2021 compared to $53.5 million, including $10.6 million of non-cash stock-based compensation expense, for the same period in 2020. For the year ended December 31, 2021, SG&A expenses were $183.5 million, including $54.9 million of non-cash stock-based compensation expense, compared to $197.0 million, including $51.8 million of non-cash stock-based compensation expense, for the same period in 2020. For the year, the decrease in SG&A expenses was primarily due to the reimbursement from Biogen of $11.3 million pursuant to the Sage/Biogen Collaboration and License Agreement, along with the impact of the restructuring that the Company announced during the second quarter of 2020. For the year, non-cash stock-based compensation expense increased because the Company incurred $6.7 million of expense in 2021 due to the achievement of milestones for certain outstanding performance restricted stock units and incurred no expense for such grants in 2020.
  • Net Income (loss): Net loss was $124.7 million for the fourth quarter of 2021 compared to net income of $974.9 million for the same period in 2020. For the year ended December 31, 2021, net loss was $457.9 million compared to net income of $606.1 million for the same period in 2020. In both periods, the decrease was due to the collaboration revenue from Biogen.

FINANCIAL GUIDANCE

  • Sage anticipates cash, cash equivalents and marketable securities of approximately $1.3 billion at the end of 2022.
  • The Company does not anticipate receipt of any milestone payments from collaborations in 2022.
  • The Company believes its cash and cash equivalents, ongoing collaboration funding, and potential revenue, will support its operations into 2025.

Conference Call Information

Sage will host a conference call and webcast today, Thursday, February 24, at 8:00 a.m. ET to discuss its fourth quarter and full year 2021 financial results and recent corporate updates. The live webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available on Sage's website approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company fearlessly leading the way to create a world with better brain health. Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. For more information, please visit. www.sagerx.com.


https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-fourth-quarter-and-full-year-2021

LIVE: Market Coverage: Thursday February 24 Yahoo Finance

Bear Market is Here

 

GAZPROM - CONTRA

 click on the arrows

cazp for contra by StockBlog on TradingView.com

Wednesday, February 23, 2022

BAYERN - GOLDEN CROSS

click on the arrows


BAYERN - GOLDEN CROSS by StockBlog on TradingView.com

Alphabet Inc. (GOOG.L) - EBITDA

 Alphabet Inc. (GOOG.L) - EBITDA

CLICK ON THE BARS


Tuesday, February 22, 2022

Monday, February 21, 2022

Saturday, February 19, 2022

Friday, February 18, 2022

TERNA ENERGY: The amendment of the Public-Private Partnership (PPP) Agreement for the Integrated Waste Management of Peloponnese Region was signed

 

The amendment of the Public-Private Partnership (PPP) Agreement for the Integrated Waste Management of Peloponnese Region was signed

The modern, socially responsible and fully integrated waste management in the Peloponnese Region, Greece, becomes a reality as of today, following the relevant amendment of the Public-Private Partnership (PPP) Agreement for the Integrated Waste Management of this region, signed between the Peloponnese Region Authority and the entity “Perivallontiki of Peloponnese’’, member of TERNA ENERGY Group.

The signing of the amended Partnership Agreement facilitates the Intermediate Waste Management period in the units of the project that have already been completed (Transitional  Waste Management Unit in Paleochouni, County of Arcadia and Waste Transfer Station in Nea Kios, County of Argolida), providing modern waste management services with the environmental protection as core priority and ensuring that public health requirements are met, offering at the same time multiple benefits to local communities which function as vital parts of the circular economy.

Verizon announces tender offers for 30 series of debt securities

 

Verizon announces tender offers for 30 series

 of debt securities

ExxonMobil starts production at Guyana's second offshore development

 ExxonMobil starts production at Guyana's second offshore development

Chevron Announces Fourth Quarter 2021 Results

 


Chevron Announces Fourth Quarter 2021 Results

Dropbox Announces Fourth Quarter and Fiscal 2021 Results

https://investors.dropbox.com/news-and-events/news-releases 

CORSAIR GAMING TO PRESENT AT THE D.A. DAVIDSON CONSUMER GROWTH CONFERENCE

 

CORSAIR GAMING TO PRESENT AT THE D.A. DAVIDSON CONSUMER GROWTH CONFERENCE

AT&T to Spin Off Interest in WarnerMedia to Shareholders

 AT&T to Spin Off Interest in WarnerMedia to Shareholders

Alphabet Announces Fourth Quarter and Fiscal Year 2021 Results more

 Alphabet Announces Fourth Quarter and Fiscal Year 2021 Results  more

Bayer raises peak sales for Nubeqa to exceed three billion euro amid positive Phase III ARASENS trial data

Bayer raises peak sales for Nubeqa to exceed three billion euro amid positive Phase III ARASENS trial data

Raise in peak sales expectations follows presentation of positive Phase III trial ARASENS with darolutamide (Nubeqa) in metastatic hormone-sensitive prostate cancer at 2022 ASCO GU Cancers Symposium and publication in The New England Journal of Medicine on February 17, 2022 / Broad development program underway with three additional ongoing or planned large clinical studies for darolutamide across a broad spectrum of prostate cancer
 
Berlin, February 17, 2022 – At the 2022 ASCO GU Cancers Symposium Bayer presented results from the Phase III ARASENS trial which demonstrated that the use of the oral androgen receptor inhibitor (ARi) darolutamide plus androgen deprivation therapy (ADT) and docetaxel significantly increased overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared to ADT plus docetaxel. Darolutamide plus ADT and docetaxel significantly reduced the risk of death by 32.5% compared to ADT plus docetaxel (HR=0.68, 95% CI 0.57-0.80; P<0.001). At the data cutoff date for the primary analysis (October 25, 2021), the median treatment duration was longer for darolutamide plus ADT and docetaxel (41.0 months) versus ADT plus docetaxel (16.7 months).

Amid these positive results Bayer raised peak sales expectation for Nubeqa™ (darolutamide) to exceed €3 billion.

“Subject to regulatory approval, the team at Bayer is excited to be able to offer even more patients suffering from prostate cancer an additional treatment option backed by strong clinical data,” said Stefan Oelrich, Member of the Board of Management of Bayer and President of the Pharmaceuticals Division. “With the confirmation of darolutamide’s clinical profile and expansion into the metastatic setting as well as the investments that we are making in clinical trials in other potential indications, we feel that Nubeqa has the potential to generate peak sales of more than 3 billion euros”.

Darolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company. Based on results from the pivotal Phase III ARAMIS trial, the compound is already approved for the treatment of patients with nmCRPC, who are at high risk of developing metastatic disease, in more than 60 markets worldwide. Results from the second Phase III ARASENS trial evaluating darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC) were presented yesterday as an oral presentation at the 2022 ASCO GU Cancer Symposium and simultaneously published in The New England Journal of Medicine. Bayer is already in discussions with health authorities worldwide regarding the submission for marketing authorization in this additional indication.

Darolutamide is being investigated in a broad development program with additional three ongoing or planned large clinical studies, to investigate its potential across prostate cancer patients from the early- to the late-stage of this disease. This includes another Phase III trial in mHSPC (ARANOTE) as well as an ANZUP-led international co-operative group Phase III trial, evaluating darolutamide as an adjuvant treatment for localized prostate cancer with very high risk of recurrence (DASL-HiCaP, ANZUP1801). Information about these trials can be found at www.clinicaltrials.gov. In addition, a study to explore the potential of darolutamide in the early setting for patients who have been treated with surgery or radiation and now see a rise in their prostate specific antigen (PSA) levels is also planned.

About Nubeqa™ (darolutamide)
Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells. The low potential for blood-brain barrier penetration for darolutamide is supported by preclinical models and neuroimaging data in healthy humans. A low blood-brain barrier penetration would explain the overall low incidence of central nervous system (CNS)-related adverse events (AEs) compared to placebo as seen in the ARAMIS and ARASENS Phase III trials and the improved verbal learning and memory observed in the darolutamide arm of the Phase II ODENZA trial.

The product is approved under the brand name Nubeqa™ in more than 60 markets around the world, including the U.S., EU, Japan, China, for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. The compound is also currently being investigated in further studies across various stages of prostate cancer, including another Phase III trial in mHSPC (ARANOTE) as well as an ANZUP-led international co-operative group Phase III trial, evaluating darolutamide as an adjuvant treatment for localized prostate cancer with very high risk of recurrence (DASL-HiCaP, ANZUP1801). Information about these trials can be found at www.clinicaltrials.gov.

Thessaloniki Port Authority Societe Anonyme EBITDA €

 Thessaloniki Port Authority Societe Anonyme   EBITDA € 



Thursday, February 17, 2022

OPAP: the VALEA FOUNDATION, and the entities controlled by, and acting in concert with, VALEA FOUNDATION and following SAZKA Group a.s.’ acquisitions from the market since 16 December 2021, indirectly control in total 48.09% of the total share capital and voting rights in OPAP



17/02/2022


SAZKA Entertainment AG operating under the brand name Allwyn (“Allwyn”) today announced that RUBIDIUM HOLDINGS LIMITED (“Rubidium”) through which Allwyn indirectly holds non-voting shares of OPAP S.A. (“OPAP”) reached an agreement with Yeonama Holdings Co. Limited (“Yeonama”) to purchase the remaining minority non-voting shares of Yeonama in SAZKA Delta AIF Variable Investment Company Ltd (“SAZKA Delta”), an entity through which Allwyn holds part of its interest in OPAP for consideration of €327.4 million (the “Transaction”). As a result, Allwyn’s economic interest (i.e. the percentage representing, regardless of control of SAZKA Delta, the participation in distributions but not the voting rights) in OPAP will increase from approximately 41.2% to approximately 48.1%. It is reminded that reference to the non-voting shares held by Yeonama was made in the Information Memorandum in relation to the voluntary tender offer launched by SAZKA Group a.s., which has been approved by the HCMC on 30 September 2019.

Taking into account the net debt and working capital of SAZKA Delta, the Transaction implies a premium of more than 10% on OPAP’s current market share price. The purchase price will be financed with cash from the balance sheet, including cash raised by the recent €600 million bond issuance.

The Transaction has no impact on the sole control exercised by VALEA FOUNDATION over SAZKA Delta, and thus no impact on the number and percentage of shares and voting rights in OPAP indirectly controlled by VALEA FOUNDATION and the entities controlled by, and acting in concert with, VALEA FOUNDATION within the meaning of Law 3556/2007, which according to latest TR-1 notification by VALEA FOUNDATION dated 7 January 2022 was equal to 47.13% as of 16 December 2021.

As of today the VALEA FOUNDATION, and the entities controlled by, and acting in concert with, VALEA FOUNDATION and following SAZKA Group a.s.’ acquisitions from the market since 16 December 2021, indirectly control in total 48.09% of the total share capital and voting rights in OPAP, as follows:



Corporate Name

Percentage


VALEA FOUNDATION

48.09


Valea Holding AG

48.09


KKCG Holding AG

48.09


KKCG AG

48.09


SAZKA Entertainment AG

48.09


SAZKA Group a.s.

48.09


Sazka Delta Management Ltd. (formerly Emma Delta Management Ltd.)

48.09


SAZKA Delta AIF Variable Capital Investment Company Ltd. (formerly Emma Delta Variable Capital Investment Company Ltd.)

48.09


SAZKA Delta Hellenic Holdings Limited (formerly Emma Delta Hellenic Holdings Limited)

48.09


Thessaloniki Port Authority Societe Anonyme NET INCOME €

 


Bayer highlights advancements of agriculture industry’s most prolific R&D pipeline


Crop Science R&D Pipeline Update 2022

Bayer highlights advancements of agriculture industry’s most prolific R&D pipelineIndustry-leading investment expected to translate to nearly €30bn peak sales potential / Game-changing Short Stature Corn advances, readying for 2023 commercial trials / More than 500 new high-performing seed hybrids and varieties deployed and greater than 300 new registrations refresh crop protection portfolio / Digital transformation well underway as Climate FieldView™ reaches more than 180 million acres; unlocks climate-smart models with expansion of Bayer Carbon Initiative



 Bayer showcases the latest in crop protection, seeds & traits and digital solutions. ...

Monday, February 14, 2022

BDSI 52 WEEK HIGH

BioDelivery Sciences International (BDSI) 52 WEEK HIGH


 

Collegium Pharma Broadens Its Pain Portfolio With $600M BioDelivery Sciences Deal


Collegium Pharmaceutical Inc (NASDAQ: COLL) will acquire BioDelivery Sciences International Inc (NASDAQ: BDSI) at $5.60 per share in an all-cash transaction...

Thessaloniki Port Authority Societe Anonyme(ATHEX)-Dividends

 Thessaloniki Port Authority Societe Anonyme(ATHEX)-Dividends

Sunday, February 13, 2022

The shares of our page with the best and worst performance of the week

 The financial and technical analycies presented on this website have not been performed by an Investment Services Company, nor have they been compiled by a certified analyst . It is simply a display and presentation of public data of Greek and foreign shares with informative and entertaining character.



European Reliance (EUPIC.AT)


Logicom (LOG.CSE)


Corsair Gaming, Inc. 





Meta Platforms (FB)


 Alphabet Inc. (GOOG.L)


Netflix (NFLX) NASDAQ


FREEDOME 24

After opening an account, you will receive a free share worth up to $ 600


COMPANY OF THE WEEK: Mytilineos (MYTIL.AT)












European Reliance: ANNOUNCEMENT FOR IMPORTANT EVENTS

 

ANNOUNCEMENT FOR IMPORTANT EVENTS


Today on 11.02.2022, the Board of Directors of the societé anonyme under the name “EUROPEAN RELIANCE GENERAL INSURANCE COMPANY S.A.” (hereinafter the Company) announces to the investors in accordance with the provisions of art. 17 para. 1 of Regulation (EU) No 596/2014 dated 16 April 2014, article 4.1.3.1. indent 5 of the Athens Exchange Rulebook, as well as any other relevant applicable provision, that during its meeting on 11.02.2022 at 18:30, the Board of Directors was informed that the company named “Allianz SE”, having its registered seat at Königinstraße 28, 80802 Munich, Federal Republic of Germany (hereinafter the Offeror) has submitted a voluntary tender offer in accordance with the provisions of Law 3461/2006, as currently in force, (hereinafter the Tender Offer) for the acquisition of the total shares of the Company for a consideration of € 7.8 per Share. The acquisition of the shares by the Offeror is subject to approvals required by the competent regulatory authorities, the Bank of Greece, the Hellenic Capital Market Commission and the Hellenic Competition Commission.

Today, the Offeror executed share purchase agreements with Company’s shareholders for the acquisition of 19.181.256 shares before the end of the Tender Offer Acceptance Period, which represent in total 72,2% of the shares and voting rights in the Company, subject to approvals required by the competent regulatory authorities, the Bank of Greece, the Hellenic Capital Market Commission and the Hellenic Competition Commission (hereinafter the Transaction). In particular the Offeror has executed share purchase agreements with the following:

1. shareholders of the Company, including Company’s executives and the CEO, for the acquisition of 5.313.400 shares representing 20.02% of shares and voting rights in the Company;

2. EBRD, for the acquisition of 4.125.552 shares representing 15.54% of shares and voting rights in the Company; and

3. other shareholders, for the acquisition of 9.742.304 shares representing 36.7% of shares and voting rights in the Company.

The long term plans of the Offeror include the integration of Company's activities with those of the Allianz Group's subsidiary in Greece with Mr. Christos Georgakopoulos as CEO, the promotion of the Company's brands and the strengthening of the Allianz Group’s role in the Greek insurance market.

The proposed participation of the Offeror in the Company's share capital and the fact that Mr. Christos Georgakopoulos shall remain in the Company's management will ensure the continuation of the Company's business strategy and operation under the same successful business principles, but will also result in achieving additional benefits which will arise from the Company's participation in a global group operating in the same sector, thus contributing to the further strengthening of the Company's position in the market.

Alphacap acts as financial advisor and law firm Zepos & Yannopoulos acts as legal advisor in relation to the Transaction.

Sunday, February 6, 2022

Friday, February 4, 2022

Bayer will discontinue phase II development candidate eliapixant


Bayer will discontinue phase II development candidate eliapixantReview of development program led to reassessment of benefit-risk ratio in all four potential indications for the investigational P2X3 receptor antagonist


Berlin, Germany, February 4, 2022 – Bayer today announced the discontinuation of Phase II development candidate eliapixant (BAY 1817080), an investigational P2X3 receptor antagonist that was being evaluated for potential indications in endometriosis, refractory chronic cough, overactive bladder and diabetic neuropathic pain. Following a review of available data, Bayer concluded that the overall benefit no longer outweighs the risk in these indications.

Eliapixant is an investigational agent and has not been approved for use in any country, for any indication.

Mytilineos S.A. (MYTIL:ATH) NET DEBT €

 Mytilineos S.A. (MYTIL:ATH) NET DEBT € 


Wednesday, February 2, 2022

VOLTA DEATH CROSS

 

VOLTA DEATH CROSS by StockBlog on TradingView.com

DISCLAIMER:

The financial and technical analycies presented on this website have not been performed by an Investment Services Company, nor have they been compiled by a certified analyst . It is simply a display and presentation of public data of Greek and foreign shares with informative and entertaining character.

My opinion on the shares of our site

Τhe situation of the stock market